Table 1 Clinical data of donor patients

				Clinical status
Case no.	Sex	Age	Histological diagnosis^a	T	N	M	Overall staging	Sample type^b	Tumor recurrence	Tumor metastasis	History of chemotherapy^c	History of RT treatment
23^d	M	65	Non-keratinizing carcinoma	2	0	0	II	Nasopharyngectomized tissue	Yes	No	No	2D-RT (66 Gy in 33 fractions)
32	F	72	Undifferentiated carcinoma	3	2	0	III	Primary biopsy	No	No	ChemoRT then adjuvant chemotherapy	IMRT (70 Gy in 33 fractions)
38^d	F	63	Moderately differentiated squamous cell carcinoma	2	0	0	II	Nasopharyngectomized tissue	Yes	No	No	2D-RT (66 Gy in 33 fractions)
43^d	M	64	Poorly differentiated carcinoma	3	0	0	III	Nasopharyngectomized tissue	Yes	Yes	ChemoRT then adjuvant chemotherapy	2D-RT (66 Gy in 33 fractions)
47^d	F	52	Undifferentiated carcinoma	3	0	0	III	Nasopharyngectomized tissue	Yes	No	ChemoRT alone	IMRT (70 Gy in 35 fractions)
53^d	M	39	Undifferentiated carcinoma	4	1	0	IVA	Nasopharyngectomized tissue	Yes	No	ChemoRT alone	IMRT (70 Gy in 35 fractions)
76	F	57	Undifferentiated carcinoma	1	0	0	I	Primary biopsy	Yes	No	No	IMRT (66 Gy in 33 fractions)

^aHistopathological properties of the NPC from which PDXs and cell lines were successfully established (from the original report from pathologists in Queen Mary Hospital)
^bPatients with newly diagnosed NPC received either curative RT or ChemoRT with or without adjuvant chemotherapy at the time of diagnosis. When NPC recurred, patients received nasopharyngectomy. Therefore, primary biopsy was obtained before any treatment, while nasopharyngectomized tissue was recurrent tumor and collected after treatment
^cPatients who had ChemoRT received cisplatin 100 mg m⁻² every 3 weeks for 3 cycles. For those who received adjuvant chemotherapy after ChemoRT, they received cisplatin 80 mg m⁻² and 5-FU 1000 mg m⁻² every 4 weeks for 3 more cycles
^dPatients who did not survive by 30 June 2018

Quick links

Search